Simultaneous EGFR and VEGF alterations in non-small cell lung carcinoma based on tissue microarrays

Cancer Informatics

Volumn 3, Issue , 2007, Pages 275-284

  Tsiambas, Evangelos ^a,c   Stamatelopoulos, Athanasios ^b   Karameris, Andreas ^a,c   Panagiotou, Ioannis ^d   Rigopoulos, Dimitrios ^d   Chatzimichalis, Antonios ^b   Bouros, Demosthenes ^e   Patsouris, Efstratios ^c  

^a 417 VA Hospital (NIMTS)   (Greece)

^b METAXA CANCER HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d 401 GENERAL MILITARY HOSPITAL OF ATHENS   (Greece)

^e DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Epidermal growth factor receptor; Genes; Non small cell lung carcinoma; Tissue microarrays; Vascular endothelial growth factor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; VASCULOTROPIN;

ADULT; ANEUPLOIDY; ARTICLE; CANCER STAGING; CHROMOSOME 7; CLINICAL ARTICLE; COMPUTER ANALYSIS; CORRELATION ANALYSIS; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LUNG NON SMALL CELL CANCER; MALE; PROTEIN DETERMINATION; SMOKING; TISSUE MICROARRAY; CONTROLLED STUDY; EGFR GENE; GENE OVEREXPRESSION; HISTOPATHOLOGY; NON SMALL CELL LUNG CANCER; PROTEIN EXPRESSION;

EID: 49649116583     PISSN: 11769351     EISSN: 11769351     Source Type: Journal    
DOI: 10.1177/117693510700300026     Document Type: Article

References (56)

1. Argiris, A., Hensing, T. et al. 2006. Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: epidermal growth factor receptor mutations do not tell the whole story. J. Thorac. Oncol., 1:52-60.
2. Awaya, H., Takeshima, Y. et al. 2005. Gene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridization and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung. J. Clin. Pathol., 58(10):1076-80.
3. Barder, T.D., Volgenstein, B. et al. 2004. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N. Engl. J. Med., 351:2883-89.
4. Baselga, J. and Arteaga, C.L. 2006. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J. Clin. Oncol., 23:2445-59.
5. Baselga, J., Pfister, D. et al. 2000. Phase I studies of antiepidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol., 18:904-14.
6. Cappuzo, F., Hirsch, F.R. et al. 2006. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non small cell lung cancer. J. Natl. Cancer Inst., 97:643-55.
7. Ciardiello, F., Bianco, R. et al. 2000. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin. Cancer Res., 6:3739-47.
8. Chang, C.C., Lin, M.T. et al. 2006. Effect of connective tissue growth factor on hypoxia-inducible factor-1α degradation and tumor angiogenesis. J. Natl. Cancer Inst., 98(14):984-95.
9. Ellis, L.M., Rosen, L. et al. 2006. Overview of anti-VEGF therapy and angiogenesis. Part 1. Angiogenesis inhibition in solid tumor malignancies. Clin. Adv. Hematol. Oncol., 4(1):suppl 1-10.
10. Ekstrand, A.J., Sugawa, N. et al. 1992. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc. Natl. Acad. Sci. U.S.A., 89:4309-13.
11. Frederick, L., Wang, X.Y. et al. 2002. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res., 60:1383-87.
12. Giaccone, G., Herbst, R.S. et al. 2004. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small cell lung cancer: a phase III-trial-INTACT 1. J. Clin. Oncol., 22:777-84.
13. Gil, J.00, Wu, H. et al. 2002. Image analysis and morphometry in the diagnosis of breast cancer. Microsc. Res. Tech., 59:109-18.
14. Gridelli, Rossi, A. et al. 2006. New antiangiogenetic agents and non-small cell lung cancer. Crit. Rev Oncol. Hematol., 3:11-15.
15. Han, S.W., Hwang, P.G. et al. 2006. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib in chemotherapy-resistant non-small cell lung cancer. Int. J. Cancer, 113:109-115.
16. Hirch, F.R., Varella-Garcia, M. et al. Epidermal growth factor receptor in non-small cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J. Clin. Oncol., 21:3798-807.
17. Hebst, R.S., Johnson, D.H. et al. 2005. Phase I/II trial evaluating the antivascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine inase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J. Clin. Oncol., 23(11):2544-55.
18. Harari, P.M. 2004. Epidermal growth factor receptor inhibition strategies in oncology. Endocr. Relat. Cancer, 11:689-708.
19. Jensen, A.D., Munter, M.W. et al. 2006. Treatment of non-small cell lung cancer with intensity-modulated radiation therapy in combination with cetuximab: the NEAR protocol. BMC Cancer, 6(1):122.
20. Ji, H., Li, D. et al. 2006. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell, 9(6):485-95.
21. Janne, P.A., Engelman, J.A. et al. 2006. Epidermal growth factor receptor mutations in non-small cell lung cancer: implications for treatment and tumor biology. J. Clin. Oncol., 23:3227-34.
22. Koynova, D.K., Tsenova, V.S. et al. 2005. Tissue microarray analysis of EGFR and HER2 oncogene copy number alterations in squamous cell carcinoma of the larynx. J. Cancer Res. Clin. Oncol., 131(3):199-203.
23. Krempien, R., Munter, M.W. et al. 2005. Randomized Phase II-Study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer-PARC study protocol. BMC Cancer, 5 (1):131.
24. Kris, M.G., Natale, R.B. et al. 2003. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine-kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA, 290:2149-158.
25. Kosaka, T., Yatabe, Y. et al. 2004. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res., 64:8919-23.
26. Langer, C.J., Natale, R.B. 2005. The emerging role of vascular endothelial growth factor receptor tyrosine-kinase inhibitors. Semin. Oncol., 32(6 Suppl 10):S23-9.
27. Liebmann, C. 2001. Regulation of MAP kinase activity by peptide receptor signaling pathway: paradigms of multiplicity. Cell Signal, 13:777-85.
28. Lyseng-Williamson, K.A., Robinson, D.M. 2006. Spotlight on bevacizumab in advanced colorectal cancer, breast cancer, and non-small cell lung cancer. BioDrugs., 20(3):193-5.
29. Molina, J., Adjei, A. 2006. The Ras/Raf/MAPK Pathway. J. Thorac. Oncol., 1:7-9.
30. Marquez, A., Wu, R. et al. 2004. Evaluation of epidermal growth factor receptor (EGFR) by Chromogenic in situ hybridization (CISH) and Immunohistochemistry (IHC) in archival gliomas using bright-field microscopy. Diagn. Mol. Pathol., 13:1-8.
31. Mukohara, T., Engelman, J.A. et al. 2005. Differential effects of gefitinib and cetuximab on non small-cell lung cancers bearing epidermal growth factor receptor mutations. J. Natl. Cancer Inst., 97(16):1185-94.
32. Matsumori, Y., Yano, S. et al. 2006. ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine-kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model. Oncol. Res., 16(1):15-26.
33. Morelli, M.P., Cascone, T. et al. 2006. Anti-tumor activity of the combination of cetuxiamb, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine-kinases. J. Cell. Physiol., 208(2):344-53.
34. Moscatello, D.K. and Holgado-Madruga, M. et al. 1995. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res, 55:5536-39.
35. Moroni, M., Veronese, S. et al. 2005. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study. Lancet. Oncol., 6: 279-86.
36. Perez-Soler, R., Chachoua, A. et al. 2004. Determination of tumor response and survival with erlotinib in patients with non-small cell lung cancer. J. Clin. Oncol., 22:3238-247.
37. Pao, W., Miller, Z. et al. 2004. EGF receptor gene mutations are common in lung cancers from ''never smokers'' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. U.S.A., 101:13306-311.
38. Pao, W., Miller, V.A. et al. 2006. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. Plos. Med., 2(3)73:225-35.
39. Park, K., Kim, J. et al. 2003. Comparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the HER2/neu status in primary breast carcinoma using tissue microarray. Mod. Pathol., 16:937-43.
40. Raben, D., Helfrich, B. et al. 2005. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin. Cancer Res., 11:795-805.
41. Rosell, R., Daniel, C. et al. 2004. Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol., 23:618a.
42. Robert, F., Blumenschein, G. et al. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naïve advanced non-small cell lung cancer. J. Ciln. Oncol., 23(36):9089-96.
43. Reinmuth, N., Brandt, B. et al. 2000. Ploidy, expression of erbB1, erbB2, P53 and amplification of erbB1, erbB2 and erbB3 in non-small cell lung cancer. Eur. Respir. J., 16:991-96.
44. Sekido, Y., Fong, K.M. et al. 2003. Molecular genetics of lung cancer. Annu. Rev. MeD., 54:73-87.
45. Strieter, R.M. 2005. Masters of angiogenesis. Nat. Med., 11(9):925-27.
46. Siemann, D.W. and Shi, W. 2004. Efficacy of combined anti-angiogenic and vascular disrupting agent in treatment of solid tumors. Int. J. Radiat. Oncol. Biol. Phys., 60:1233-40.
47. Thienelt, C.D., Bunn, P.A. Jr. et al. 2005. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small cell lung cancer. J. Clin. Oncol., 23(34):8786-93.
48. Thorpe, P.E. 2004. Vascular targeting agents as cancer therapeutics. Clin. Cancer Res., 10:415-27.
49. Tateishi, M., Ishida, T. et al. 1990. Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. Cancer Res., 12:1183-88.
50. Takizawa, H., Kondo, K. et al. 2006. The balance of VEGF-C and VEGFR-3 mRNA is a predictor of lymph node metastasis in non-small cell lung cancer. Br. J. Cancer, 95(1):75-9.
51. Tsiambas, E., Karameris, A. et al. 2006a. EGFR alterations in pancreatic ductal adenocarcinoma: a Chromogenic in situ Hybridization analysis based on tissue microarrays. Hepato-Gastroenterology, 53:452-57.
52. Tsiambas, E., Karameris, A. et al. 2006b. HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis. JOP, 7(3):283-94.
53. Tsiambas, E., Stavrakis, I. et al. 2006c. Evaluation of epidermal growth factor receptor gene and chromosome 7 alterations in squamous cell carcinoma of the larynx, using chromogenic in situ hybridization on tissue microarrays. J. Laryngol. Otol., 2:1-8.
54. Voelkel, N.F., Vandivier, R.W. et al. 2006. Vascular endothelial growth factor in the lung. Am. J. Physiol. Lung. Cell. Mol. Physiol., 290(2):L209-21.
55. Yang, S.H., Mechanic, L.E. et al. 2006. Mutations in the tyrosine-kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. Clin. Cancer Res., 11:2106-110.
56. Zhu, C.Q., Shin, W. et al. 2006. Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J. Clin. Pathol., 59(8):790-800.